WASHINGTON, D.C. (October 19, 2023) – The Biosimilars Council applauds the House Committee on Energy and Commerce Subcommittee on Health for its consideration of H.R. 1352, the Increasing Access to Biosimilars Act of 2023. Introduced by Rep. Hudson, this important legislation would enhance patient access to biosimilars through the creation of a voluntary, shared savings demonstration program in Medicare Part B. The bill would reward new adoption by providers of these lower-cost, life-saving treatments, which in turn would expand patient access and return meaningful savings to taxpayers. The Biosimilars Council looks forward to working with the committee to ensure passage of this timely legislation as it continues its efforts to strengthen patient access to medicines in Medicare.
For media inquiries, contact the Communications department at [email protected].
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but less than 18 percent of total drug spending.